• Administrator

    CDSS #SideEffects Video

    The Medical Research Council (MRC) Centre for Drug Safety Science, based at the University of Liverpool, along with Sense about Science, have jointly launched a new animation: “10½ things you may not know about side effects.”

    Developed following public workshops, the animation is designed to help people learn more about side effects - why they occur, how to manage them and how medicines can be made safer by reporting them.

    The 10½ things highlighted include:

    • Every medicine has side effects: All medicines have side effects but are tested to check that, for most people, the benefit of taking the medicine far outweighs the side effects.
    • Giving medicines the yellow card: We can all help to improve drug safety by reporting side effects. Through the MHRA Yellow Card app we can report effects we, or those we care for, have experienced.
    • Food can amplify side effects: Certain foods can compromise, reverse or amplify the effects of different medications. Grapefruit juice is well known for amplifying effects, leafy greens can reverse effects and there’s such a thing as the ‘cheese reaction’.
    • Herbal supplements can interact with medicines: for example, St John’s Wort interacts with 903 medicines, 264 of them seriously.
    • Some side effects are beneficial: Viagra started its life as a treatment for angina, then its beneficial side effect led to it becoming the world’s most successful treatment for impotence.

    By raising awareness of side-effects and what can cause them, the MRC Centre for Drug Safety Science and Sense about Science hope that more people will report side effects and be better able to manage their health.

    The animation and  companion guide can both be downloaded by visiting www.liverpool.ac.uk/drug-safety/drug-safety/

    Professor Sir Munir Pirmohamed, Director of the MRC Centre for Drug Safety Science, said: “Medicines have helped to treat or cure numerous diseases. Yet all medicines can cause side effects. Our research centre, funded by the Medical Research Council, studies these side effects. Our work aims to improve medicines for all,  by developing strategies that can predict, prevent or diagnose harm from medicines, so that we and others can make them even more beneficial and safe.”

    Rebecca Asher, Deputy Director at Sense about Science, said: “People are often surprised to discover that side effects are normal. Now we have longer life expectancy and some previously fatal conditions can be managed with medicines, the need for a common understanding of what’s meant by side effects, why they happen and what to do about them is urgent."

    Jane Burns, who took part in the public workshop in Liverpool, said:  “The animation is brilliant, really informative. It’s important that the public know that they need to tell their doctors everything that they are taking, even herbal products, so that they have all the information. Also, patients need to be aware that it’s ok to experience some side effects, as long as the benefits outweigh any minor discomfort.”

    Mick Foy, group manager for MHRA’s Vigilance and Risk Management of Medicines division said: “Our priority, as regulator, is to make sure the medicines you and your family take are effective and acceptably safe. The reporting of suspected side effects is vital in helping us achieve this.

    “Everyone, from healthcare professionals to patients themselves, can help make medicines safer by reporting any suspected side effects easily and quickly through our Yellow Card Scheme online or via the free mobile app.”

  • Administrator

    Cancer Research UK is on a mission to detect cancer sooner

    Cancer Research UK (CRUK) are focusing their efforts to help detect cancer earlier and significantly improve survival chances.


    For most cancers, the earlier it is detected and treated, the better the outcome. Take colorectal cancer, patients diagnosed at stage 1 have over a 95% survival chance, whereas those diagnosed at stage 4 have less than 8% survival chance1 and significantly higher costs of care2. However strikingly, close to half of all cancers are diagnosed at a late stage in the UK and it’s become CRUK’s mission to drive change, support researchers in detecting cancer at the earliest possible stage, and increase survival chances. To help them achieve their ambitious goal to see three-quarters of people with cancer surviving the disease by 2034, they’ve launched a number of initiatives in this area.

    To increase, encourage and support transformative cancer early detection research, CRUK has rolled out new funding specific for this field of research, including several new funding streams from £20,000 – £2.5 million. The funding committee encourages high-risk, disruptive research, as well as international and industry collaboration.

    To drive innovation and novel ground-breaking research, CRUK has teamed up with EPSRC and STFC to hold a series of three-day Innovation Sandpit Workshops, where they bring together multidisciplinary researchers to develop new ideas and solutions for the biggest challenges facing the early detection of cancer field. Researchers with the best ideas walk away with £100,000 seed funding to commence the project.

    CRUK is focusing on improving the translation of novel cancer diagnostics and technologies. They are actively encouraging collaboration with industry through their grants, and are connecting academics with commercial researchers through a number of mechanisms, including a series of networking events that are held in partnership with Innovate UK and the Knowledge Transfer Network.

    Through the Early Detection of Cancer Conference, held in partnership with the Canary Centre at Stanford University and the Knight Cancer Institute at Oregon Health & Sciences University, CRUK is bringing together researchers working on cancer early detection from across the globe. The three-day event encompasses world-leading research, novel discoveries, scientific debate and plenty of networking. The next conference will be held on 24-26 September 2019 in San Francisco.

    To unite the world’s brightest minds and drive game-changing research, CRUK is launching the International Cancer Early Detection (ICED) Alliance, a virtual research centre between six lead sites in the UK and the US. The Alliance will leverage key strengths at each site, driving novel collaborative research to accelerate progress in the field.

    Finally, CRUK believes that it’s crucial to encourage and support the next generation of early detection researchers. To assist them, they’ve made the early detection of cancer a priority area for their Career Development Fellowship scheme.

    And this is just the beginning - to stay on top of new initiatives and opportunities as they are rolled out, email their team on This email address is being protected from spambots. You need JavaScript enabled to view it. to join our mailing list.

    1Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival#ref-3, Accessed January 2019.

    2Cancer Research UK (2014), Saving lives, averting costs, Cancer Research UK.

  • Administrator

    UKPGx Chair Appointed to NHS Board

    NHS England’s Chair, Lord David Prior, has welcomed the appointment of one of the country’s leading experts in genetics and personalised medicine, based at the University of Liverpool, to the organisation’s board.

    Professor Sir Munir Pirmohamed, who is based at the University’s Institute of Translational Medicine, has been appointed by the Secretary of State as a non-executive director of NHS England. Among other posts, he is the David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics at the University, and Director of the MRC Centre for Drug Safety Science and Wolfson Centre for Personalised Medicine. Professor Pirmohamed is also the Founder and Chair of the UK Pharmacogenetics & Stratified Medicine Network.

    His work has seen him at the forefront of research into the personalisation and safety of medicines based on an individual’s genetic make-up, and he was awarded a Knighthood in the Queen’s birthday honours in June 2015 for services to Medicine.

    Lord Prior, said: “The NHS stands on the brink of being able to harness the benefits of genomic research to provide ever-more precise a2nd safe treatment for patients with a wide range of conditions. The completion of the 100,000 Genomes project puts the UK at the leading edge of a fundamental breakthrough in medical science. How we incorporate genomic medicine into the NHS, and combine genomic data with NHS data to stimulate research into further tests and treatments, is the greatest opportunity in a generation to improve the health of people in England, and indeed the rest of the world.

    “As one of the world’s leading experts in this field, Professor Pirmohamed will bring invaluable knowledge and expertise to the table as we seek to make the most of this opportunity, and deliver as much benefit to patients as possible.

    “I look forward to working with him and other colleagues in the New Year, as we will also be working to translate the important ambitions which will be set out in the NHS Long Term Plan into real improvements for patients in every part of England.”

    Professor Pirmohamed’s appointment takes effect from 1 January 2019, for a period of three years, and was made following the established process for appointments to public boards.

  • Administrator

    100,000 Genomes Sequenced in the NHS

    Health Secretary Matt Hancock has announced that the 100,000 Genomes Project, led by Genomics England in partnership with NHS England, has reached its goal of sequencing 100,000 whole genomes from NHS patients.

    This ground-breaking programme was launched by then-Prime Minister David Cameron in 2012, with the goal of harnessing whole genome sequencing technology to uncover new diagnoses and improved treatments for patients with rare inherited diseases and cancer. The task was to make the UK a world leader within five years.

    The 100,000 Genomes Project has delivered life-changing results for patients with one in four participants with rare diseases receiving a diagnosis for the first time, and providing potential actionable findings in up to half of cancer patients where there is an opportunity to take part in a clinical trial or to receive a targeted therapy.

    To do this Genomics England worked with NHS England to create 13 NHS Genomic Medicine Centres (GMCs) to support the project, a state-of-the-art sequencing centre run by Illumina, Inc. and an automated analytics platform to return whole genome analyses to the NHS.

    Genomics England and NHS England are extremely grateful to the 85,000 participants, 1,500 NHS staff, over 3,000 researchers, the National Institute for Health Research and the UK Government whose support and funding have been key to the success of this pioneering NHS transformation programme.

    As a result the UK has become the first nation in the world to apply whole genome sequencing at scale in direct healthcare, as well as providing access to high quality de-identified clinical and genomic data for research aimed at improving patient outcomes.

    The project has laid the foundations for a NHS Genomic Medicine Service, which will provide equitable access to genomic testing to patients across the NHS from 2019.

    Health Secretary Matt Hancock said:

    Sequencing the 100,000th genome is a major milestone in the route to the healthcare of the future. From Crick and Watson onwards, Britain has led the world in this amazing technology. We do so again today as we map a course to sequencing a million genomes. Understanding the human code on such a scale is part of our mission to provide truly personalised care to help patients live longer, healthier and happier lives.

    I’m incredibly excited about the potential of this type of technology to unlock the next generation of treatments, diagnose diseases earlier, save lives and enable patients to take greater control of their own health.

    Sir John Chisholm, Chair of Genomics England, said:

    At launch the 100,000 Genomes Project was a bold ambition to corral the UK’s renowned skills in genomic science and combine them with the strengths of a truly national health service in order to propel the UK into a global leadership position in population genomics. With this announcement, that ambition has been achieved. The results of this will be felt for many generations to come as the benefits of genomic medicine in the UK unfold.

    Professor Mark Caulfield, Chief Scientist at Genomics England, said:

    The sequencing of 100,000 whole genomes marks an extraordinary UK achievement that is transforming the application of genomics in our NHS. Genomics England will continue to analyse these genomes alongside life course clinical information to reveal answers for as many participants as possible and improve their NHS care. With the generous support of our participants, the NHS, the National Institute for Health Research and the Government we will continue to ensure the UK’s global leadership in genomic healthcare.

     Professor Dame Sue Hill, Chief Scientific Officer for England and Senior Responsible Officer for Genomics at NHS England, said:

    This achievement has only been possible because of the amazing commitment and contribution of NHS teams across the country and I would like to thank each and every one of them for rising to this challenge and excelling in its delivery.

    The results, which will continue to be returned to patients, show how genomic medicine can transform lives, bringing quicker and better diagnoses and increasing the number of patients surviving cancer, and the opportunity now is for the NHS to turn this research into reality by introducing sequencing technology as part of our world-leading NHS Genomic Medicine Service.

     Jillian Hastings Ward, Chair of the National 100,000 Genomes Project Participant Panel, said:

    This is a fantastic milestone. Thanks to the dedication and hard work of the whole project team, patients and their families are starting to receive life-changing diagnoses. We look forward to seeing more results in the near future – for the rest of the project participants, and for the wider public who will soon benefit from genomic medicine in the NHS. We will also keep working with Genomics England to make sure they keep patients’ interests at the heart of all they do.

    Francis deSouza, President and CEO of Illumina, Inc., said:

    We congratulate Genomics England and the NHS for reaching this historic achievement and are honored to be part of it.  The accomplishment of the 100,000th genome is only the beginning in many respects, but a significant step towards realizing the promise of genomic medicine to develop products for earlier detection and treatment of many rare diseases and cancers.

    James Fenton, Project Manager at the NIHR National Biosample Centre – the facility that stores and processes samples for the 100,000 Genomes Project – said:

    It has been a unique study to have been part of and a fantastic achievement on all fronts, really demonstrating that the UK is leading the way in genomic research towards personalised medicine. This milestone is testament to the hard work and dedication put in by all at National Institute for Health Research National Biosample Centre and our partners in Genomics England, the NHS GMCs and Illumina.

    Find out more at the Genomics England website.

Contact Us

University of Liverpool

Block A: Waterhouse Buildings

1-5 Brownlow Street

Liverpool L69 3GL

Email: cjmcn@liverpool.ac.uk

Follow us